Rajesh Malik G1 Therapeutics, Inc. (GTHX) insider trading activity

Rajesh Malik is Chief Medical Officer of G1 Therapeutics, Inc.. Currently has a direct ownership of 0 shares of GTHX, which is worth approximately $0. The most recent transaction as insider was on Sep 18, 2024, when has been sold 89,762 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Rajesh Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 18 2024	SELL Sale (or disposition) back to the issuer	-	89,762 Reduced 50.65%	87,450 Common Stock
Sep 18 2024	SELL Disposition due to a tender of shares in a change of control transaction	-	87,450 Reduced 100.0%	0 Common Stock
Sep 18 2024	BUY Grant, award, or other acquisition	-	17,900 Added 9.17%	177,212 Common Stock
Jul 05 2024	SELL Open market or private sale	$6,212 $2.51 p/Share	2,475 Reduced 1.53%	159,312 Common Stock
May 13 2024	SELL Open market or private sale	$39,043 $4.79 p/Share	8,151 Reduced 4.8%	161,787 Common Stock
Feb 12 2024	SELL Open market or private sale	$132,132 $4.62 p/Share	28,600 Reduced 14.41%	169,938 Common Stock
Feb 12 2024	BUY Exercise of conversion of derivative security	$8,580 $0.3 p/Share	28,600 Added 12.59%	198,538 Common Stock
Jan 04 2024	SELL Open market or private sale	$2,119 $2.94 p/Share	721 Reduced 0.42%	169,938 Common Stock
Jan 03 2024	SELL Open market or private sale	$9,419 $3.12 p/Share	3,019 Reduced 1.74%	170,659 Common Stock
Jan 03 2024	BUY Grant, award, or other acquisition	-	37,300 Added 17.68%	173,678 Common Stock
Dec 11 2023	SELL Open market or private sale	$119,790 $3.54 p/Share	33,839 Reduced 19.88%	136,378 Common Stock
Dec 11 2023	BUY Exercise of conversion of derivative security	$11,843 $0.35 p/Share	33,839 Added 18.53%	148,778 Common Stock
Jul 05 2023	SELL Open market or private sale	$3,334 $2.45 p/Share	1,361 Reduced 0.99%	136,378 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	-	35,000 Added 20.26%	137,739 Common Stock
Jan 05 2023	SELL Open market or private sale	$3,943 $5.41 p/Share	729 Reduced 0.7%	102,739 Common Stock
Jan 04 2023	SELL Open market or private sale	$9,145 $5.58 p/Share	1,639 Reduced 1.56%	103,468 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	17,900 Added 14.55%	105,107 Common Stock
Dec 15 2022	BUY Exercise of conversion of derivative security	$4,200 $0.3 p/Share	14,000 Added 13.83%	87,207 Common Stock
Sep 13 2022	SELL Open market or private sale	$282,780 $15.71 p/Share	18,000 Reduced 19.74%	73,207 Common Stock
Sep 13 2022	BUY Exercise of conversion of derivative security	$7,020 $0.39 p/Share	18,000 Added 16.48%	91,207 Common Stock
Jul 05 2022	SELL Open market or private sale	$3,350 $5.17 p/Share	648 Reduced 0.88%	73,207 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	$3,000 $0.3 p/Share	10,000 Added 11.93%	73,855 Common Stock
Jan 05 2022	SELL Open market or private sale	$15,331 $10.61 p/Share	1,445 Reduced 2.21%	63,855 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	12,000 Added 15.52%	65,300 Common Stock
May 10 2021	BUY Exercise of conversion of derivative security	$3,000 $0.3 p/Share	10,000 Added 15.8%	53,300 Common Stock

Also insider at

PNT

POINT Biopharma Global Inc. Healthcare

Director

Rajesh Malik

Chief Medical Officer

Research Triangle Park, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GTHX shares.

Notify only if

Value

Insider Trading

Get notified when an G1 Therapeutics, Inc. insider buys or sells GTHX shares.

Notify only if

Operation

Value

Type

News

Receive news related to G1 Therapeutics, Inc.

Track Activities on GTHX

Account